The antidiabetic effect of ginsenoside Rb2 via activation of AMPK

Arch Pharm Res. 2011 Jul;34(7):1201-8. doi: 10.1007/s12272-011-0719-6. Epub 2011 Aug 3.

Abstract

Ginsenosides, which are active compounds found in ginseng (Panax ginseng), are used as antidiabetic treatments. The aim of this study was to determine whether Rb2, a type of ginsenoside, regulates hepatic gluconeogenesis through AMP-activated protein kinase (AMPK) and the orphan nuclear receptor small heterodimer partner (SHP) in hyperlipidemic conditions used as an in vitro model of type 2 diabetes. Considering these results, we concluded that Rb2 may inhibit palmitate-induced gluconeogenesis via AMPK-induced SHP by relieving ER stress, a cause of gluconeogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / metabolism*
  • Animals
  • Diabetes Mellitus, Type 2 / drug therapy
  • Gene Silencing / drug effects
  • Ginsenosides / metabolism
  • Ginsenosides / pharmacology*
  • Gluconeogenesis / drug effects
  • Glucose / analysis
  • Glucose / biosynthesis
  • Hepatocytes / drug effects
  • Hypoglycemic Agents / metabolism
  • Hypoglycemic Agents / pharmacology*
  • Liver / drug effects
  • Liver / metabolism
  • Phosphorylation / drug effects*
  • Protein Tyrosine Phosphatase, Non-Receptor Type 6 / drug effects
  • RNA / analysis
  • Rats
  • Transfection

Substances

  • Ginsenosides
  • Hypoglycemic Agents
  • ginsenoside Rb2
  • RNA
  • AMP-Activated Protein Kinases
  • Protein Tyrosine Phosphatase, Non-Receptor Type 6
  • Ptpn6 protein, rat
  • Glucose